D. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $10.00 target price on the stock.

Tevogen Bio Price Performance

NASDAQ:TVGN traded up $0.06 during mid-day trading on Monday, reaching $1.15. The company's stock had a trading volume of 147,013 shares, compared to its average volume of 5,099,675. Tevogen Bio has a 12-month low of $0.26 and a 12-month high of $3.09. The firm's fifty day moving average price is $1.07 and its two-hundred day moving average price is $1.29.

Insider Activity

In other news, insider Neal Flomenberg sold 70,384 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $1.09, for a total transaction of $76,718.56. Following the completion of the sale, the insider now owns 3,898,828 shares of the company's stock, valued at $4,249,722.52. This represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 406,510 shares of company stock valued at $446,763 in the last quarter. 56.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tevogen Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Tevogen Bio during the 4th quarter valued at about $38,000. JPMorgan Chase & Co. increased its holdings in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after acquiring an additional 16,695 shares in the last quarter. Barclays PLC increased its holdings in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after acquiring an additional 12,847 shares in the last quarter. XTX Topco Ltd purchased a new stake in Tevogen Bio in the 4th quarter worth approximately $55,000. Finally, Northern Trust Corp increased its holdings in Tevogen Bio by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after acquiring an additional 13,595 shares in the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.